| Title: |
2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer |
| Authors: |
Loverix, Liselore; Salihi, Rawand; van Rompuy, Anne-Sophie; Vanderstichele, Adriaan; van Nieuwenhuysen, Els; Baert, Thaïs; Debruyne, Philip; Cornez, Nathalie; Henry, Stéphanie; Neven, Patrick; Han, Sileny; Berteloot, Patrick; Olbrecht, Siel; Laga, Tina; Busschaert, Pieter; van Gorp, Toon; Vergote, Ignace |
| Source: |
Cervical cancer ; page A51.1-A51 |
| Publisher Information: |
BMJ Publishing Group Ltd |
| Publication Year: |
2022 |
| Document Type: |
conference object |
| Language: |
unknown |
| DOI: |
10.1136/ijgc-2022-esgo.111 |
| DOI: |
10.1136/ijgc-2022-ESGO.111 |
| Availability: |
https://doi.org/10.1136/ijgc-2022-esgo.111; https://syndication.highwire.org/content/doi/10.1136/ijgc-2022-ESGO.111 |
| Accession Number: |
edsbas.2C6243BF |
| Database: |
BASE |